MSA-2

Research use only, not for human use.

MSA-2, a potent and orally available non-nucleotide STING agonist, has EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 shows antitumor activity and stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models.

MSA-2, a potent and orally available non-nucleotide STING agonist, has EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 shows antitumor activity and stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models.

——

MSA-2 dosed via either PO or SC regimens achieved comparable exposure in both tumor and plasma. MSA-2 also exhibits dose-dependent antitumor activity when administered by IT, SC, or PO routes, and dosing regimens were identified that induced complete tumor regressions in 80 to 100% of treated animals.MSA-2 (PO: 60 mg/kg or SC: 50 mg/kg; single dose) that effectively inhibits tumor growth induced substantial elevations of IFN-β, interleukin-6 (IL-6), and TNF-α in tumor. Animal Model:MC38 tumor-bearing C57BL6 mice Dosage:60 mg/kg Administration:P.o. ; s.c (50 mg/kg); single dose Result:PO or SC doses of MSA-2 that effectively inhibited tumor growth induced substantial elevations of IFN-β, interleukin-6 (IL-6), and TNF-α in tumor.

——

Immunology/Inflammation

STING

——

——

——

129425-81-6

294.32

O=C(C1=CC(C(S1)=C2)=CC(OC)=C2OC)CCC(O)=O

>98% (HPLC)

DMSO : 50 mg/mL (169.88 mM; ultrasonic and warming and heat to 80°C)

O=C(C1=CC(C(S1)=C2)=CC(OC)=C2OC)CCC(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years